Understanding non-muscle invasive bladder cancer and its treatment options
Transcriptomic classification of non-muscle invasive bladder cancer and its clinical and prognostic implication
This study is looking to help people with non-muscle invasive bladder cancer by finding better ways to predict if their cancer might come back and to see who might not do well with the usual treatment, so they can get more personalized care based on their unique tumor traits.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10907672 on NIH RePORTER |
What this research studies
This research focuses on improving the management of non-muscle invasive bladder cancer (NMIBC), which is a common form of bladder cancer. It aims to develop tools that can predict the risk of cancer recurrence and identify patients who may not respond well to the standard treatment, Bacillus Calmette-Guerin (BCG) therapy. By analyzing the genetic information of tumors, the study seeks to create a more personalized approach to treatment, ensuring that patients receive the most effective care based on their specific cancer characteristics. This research builds on a large cohort of NMIBC patients to validate its findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-muscle invasive bladder cancer who are undergoing or considering BCG therapy.
Not a fit: Patients with muscle-invasive bladder cancer or those who have not been diagnosed with bladder cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with non-muscle invasive bladder cancer, potentially reducing recurrence rates and improving overall outcomes.
How similar studies have performed: Previous research has shown promise in using transcriptomic analysis for bladder cancer, but this specific focus on non-muscle invasive cases is relatively novel.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Tang, Li — Roswell Park Cancer Institute Corp
- Study coordinator: Tang, Li
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.